 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
6 News |  |
- || radiolabeled SSTR2 modulating peptides / Lantheus
P1 data, Journal: Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177 Lu-Satoreotide Tetraxetan. (Pubmed Central) - Sep 23, 2020
In this trial of heavily treated NETs, preliminary data are promising for the use of Lu-satoreotide tetraxetan. Additional studies are on-going to determine optimal therapeutic dose/schedule.